MIDDLETON, WI - May 4, 2016 - PharmaSeek LLC, an Investigative Site Network (ISN), is expanding the reach of its network by partnering with the Puerto Rico Consortium for Clinical Investigation (PRCCI). PRCCI is a newly established not-for-profit cooperative comprised of multiple clinical research sites throughout Puerto Rico. Through a collaborative network of investigators and the support of PharmaSeek, PRCCI will promote and enhance clinical research and drug development in Puerto Rico. PharmaSeek will use their many years of experience as an ISN to help PRCCI build and grow a network of their own. The setup of PRCCI's network will largely mirror that of PharmaSeek, which has grown to over 250 research sites throughout the US and Canada, and represents research in nearly all therapeutic areas. In addition to study identification, PharmaSeek will provide assistance with site feasibility, contract and budget negotiation, and accounts receivable. At the forefront of these efforts will be PharmaSeek's Director of Network Operations, Jill Shilbauer, who will be stationed in Puerto Rico to provide on-site support. While Puerto Rico has never been known as a hub for clinical trials, studies show that the quality of their research is equivalent to that of the United States. Furthermore, participation of Puerto Rican volunteers would help to meet the long-standing need for greater diversity in clinical trials put forth by the FDA. Despite these factors, clinical trials in Puerto Rico have decreased by nearly 50% since 2008, a statistic PharmaSeek and PRCCI hope to quickly reverse. A five-year strategy will establish the foundation for the network's growth, laying the groundwork for three five-year increments in which PRCCI develops a clinical research hub, followed by a regional center of excellence for clinical research, and finally a Bio-island in 2030. Many aspects of Puerto Rico make the island a favorable location for research. Its strategic geographic location allows access to the United States for expertise, in addition to Central and South America for multi-site trials. Furthermore, Puerto Rico boasts a favorable regulatory environment with US FDA regulation, as well as a world class business environment of international airports, foreign trade zones, mass transit, and an island-wide broadband and fiber optic network. The development of PRCCI will not only boost the clinical research industry, but the livelihood of Puerto Ricans as well. PRCCI's growth is expected to improve the local economy, promote Puerto Rico as a place of research and development, and create jobs. The network also gives Puerto Ricans a chance to participate in clinical research and gain access to treatments that are not yet commercially available. To learn more about this partnership, contact PharmaSeek at info@pharmaseek.com, or PRCCI at contact@prcci.org.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.